Amgen Enbrel Projections Include 3-Month Cushion For Immunex Plant
Executive Summary
Amgen's financial forecasts for the Immunex acquisition include a three-month cushion on the start-up date for a new production plant for Enbrel.
You may also be interested in...
Amgen’s Busy Week: Firm Acquires Panitumumab Partner Abgenix, Starts BLA
Amgen's acquisition of its development partner Abgenix will give the firm a stronger base to launch the metastatic colorectal cancer treatment panitumumab
Amgen’s Busy Week: Firm Acquires Panitumumab Partner Abgenix, Starts BLA
Amgen's acquisition of its development partner Abgenix will give the firm a stronger base to launch the metastatic colorectal cancer treatment panitumumab
Amgen/Wyeth Enbrel Supplies Replenished With Rhode Island Plant Approval
Amgen and Wyeth are in a position to resume full promotion of the rheumatoid arthritis agent Enbrel following FDA approval of a new manufacturing site in Rhode Island